Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies

British Journal of Cancer

Volumn 111, Issue 9, 2014, Pages 1772-1779

  Roy, R ^a,b   Zurakowski, D ^a,b   Wischhusen, J ^a   Frauenhoffer, C ^c   Hooshmand, S ^c   Kulke, M ^b,c   Moses, M A ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

MMP 2; pancreatic cancer; TIMP 1; urinary biomarker

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; MMP2 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; URINALYSIS; ZYMOGRAPHY; CARCINOMA, PANCREATIC DUCTAL; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; URINE;

ADULT; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 84908571584     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.462     Document Type: Article

References (56)

1. Ballehaninna U, Chamberlain R (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3: 105-119.
2. Bramhall S, Stamp G, Dunn J, Lemoine N, Neoptolemos J (1996) Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 73: 972-978.
3. Brand R, Nolen B, Zeh H, Allen P, Eloubeidi M, Goldberg M, Elton E, Arnoletti J, Christein J, Vickers S, Langmead C, Landsittel D, Whitcomb D, Grizzle W, Lokshin A (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17: 805-816.
4. Brune K, Lau B, Palmisano E, Canto M, Goggins M, Hruban R, Klein A (2010) Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 102: 119-126.
5. Canto M, Goggins M, Hruban R, Petersen G, Giardiello F, Yeo C, Fishman E, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy S, Kalloo A (2006) Screening for early pancreatic neoplasia in high-risk individuals: A prospective controlled study. Clin Gastroenterol Hepatol 4: 766-781quiz 665.
6. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, Lemoine N (2002) Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21: 4587-4594.
7. Durlik M, Gardian K (2012) Metalloproteinase 2 and 9 activity in the development of pancreatic cancer. Pol Przegl Chir 84: 377-382.
8. Evans J, Ghaneh P, Kawesha A, Neoptolemos J (1997) Role of matrix metalloproteinases and their inhibitors in pancreatic cancer. Digestion 58: 520-528.
9. Faca V, Song K, Wang H, Zhang Q, Krasnoselsky A, Newcomb L, Plentz R, Gurumurthy S, Redston M, Pitteri S, Pereira-Faca S, Ireton R, Katayama H, Glukhova V, Phanstiel D, Brenner D, Anderson M, Misek D, Scholler N, Urban N, Barnett M, Edelstein C, Goodman G, Thornquist M, McIntosh M, DePinho R, Bardeesy N, Hanash S (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5: E123.
10. Goggins M (2005) Molecular markers of early pancreatic cancer. J Clin Oncol 23: 4524-4531.
11. Goggins M (2007) Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 34: 303-310.
12. Kaur S, Baine M, Jain M, Sasson A, Batra S (2012) Early diagnosis of pancreatic cancer: Challenges and new developments. Biomark Med 6: 597-612.
13. Klein A (2011) Genetic susceptibility to pancreatic cancer. Mol Carcinog 51: 14-24.
14. Kulke M, Siu L, Tepper J, Fisher G, Jaffe D, Haller D, Ellis L, Benedetti J, Bergsland E, Hobday T, Van Cutsem E, Pingpank J, Oberg K, Cohen S, Posner M, Yao J (2011) Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29: 934-943.
15. Lekstan A, Olakowski M, Jablonska B, Labuzek K, Olakowska E, Filip I, Lampe P (2013) Concentration of gelatinases and their tissue inhibitors in pancreatic inflammatory and neoplastic tumors and their influence on the early postoperative course. Pol Przegl Chir 85: 65-72.
16. Li D, Xie K, Wolff R, Abbruzzese J (2004) Pancreatic cancer. Lancet 363: 1049-1057.
17. Maitra A, Hruban R (2008) Pancreatic cancer. Annu Rev Pathol 3: 157-188.
18. Matsuyama Y, Takao S, Aikou T (2002) Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 80: 105-110.
19. Modlin IM, Gustafsson B, Moss S, Pavel M, Tsolakis A, Kidd M (2010) Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17: 2427-2443.
20. Modlin I, Oberg K, Chung D, Jensen R, de Herder W, Thakker R, Caplin M, Delle Fave G, Kaltsas G, Krenning E, Moss S, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9: 61-72.
21. Moses M, Wiederschain D, Loughlin K, Zurakowski D, Lamb C, Freeman M (1998) Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58: 1395-1399.
22. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M (2009) Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: Metalloproteinase-9 as an independent prognostic factor. Pancreas 38: 613-618.
23. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, Davaris P (2002) Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197: 307-313.
24. Nolen B, Lokshin A (2011) The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid. Int J Biol Markers 26: 141-152.
25. Ozkan H, Kaya M, Cengiz A (2003) Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology 50: 1669-1674.
26. Pan S, Chen R, Crispin D, May D, Stevens T, McIntosh M, BronnerM, Ziogas A, Anton-Culver H, Brentnall T (2011) Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 10: 2359-2376.
27. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning E, de Herder W, Goede A, Caplin M, Oberg K, Reubi J, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80: 394-424.
28. Poley J, Kluijt I, Gouma D, Harinck F, Wagner A, Aalfs C, van Eijck C, Cats A, Kuipers E, Nio Y, Fockens P, Bruno M (2009) The yield of first-Time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104: 2175-2181.
29. Pories S, Zurakowski D, Roy R, Lamb C, Raza S, Exarhopoulos A, Scheib R, Schumer S, Lenahan C, Borges V, Louis G, Anand A, Isakovich N, Hirshfield-Bartek J, Wewer U, Lotz M, Moses M (2008) Urinary metalloproteinases: Noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 17: 1034-1042.
30. Poruk K, Firpo M, Scaife C, Adler D, Emerson L, Boucher K, Mulvihill S (2013) Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 42: 193-197.
31. Roy R, Coticchia C, Yang J, Moses M (2010) Biomarkers in cancer biology. In: Biomarkers of Toxicity: A New Era in Medicine, Vaidya V, Bonaventure J (eds), pp 355-380. John Wiley and Sons: NY, USA.
32. Roy R, Louis G, Loughlin K, Wiederschain D, Kilroy S, Lamb C, Zurakowski D, Moses M (2008) Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14: 6610-6617.
33. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses M (2011) ADAM12 transmembrane and secreted isoforms promote breast tumor growth: A distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem 286: 20758-20768.
34. Roy R, Wewer U, Zurakowski D, Pories S, Moses M (2004) ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 279: 51323-51330.
35. Sandblom G, Granroth S, Rasmussen I (2008) TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci 113: 57-64.
36. Schneiderhan W, Diaz F, Fundel M, Zhou S, Siech M, Hasel C, Moller P, Gschwend J, Seufferlein T, Gress T, Adler G, Bachem M (2007) Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay. J Cell Sci 120: 512-519.
37. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E (2001) Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 12(Suppl 2): S69-S72.
38. Slater E, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Matthai E, Chaloupka B, Gress T, Langer P, Bartsch D (2013) LCN2 and TIMP1 as potential serum markers for the early detection of familial pancreatic cancer. Transl Oncol 6: 99-103.
39. Smith E, Manfredi M, Scott R, Black P, Moses M (2007) A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: Case report. Neurosurgery 60: E1148-E1149discussion E1149.
40. Smith E, Zurakowski D, Saad A, Scott R, Moses MA (2008) Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14: 2378-2386.
41. Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G, Blasi F, Talamini G, Bassi C, Scarpa A (2011) Elevated urinary levels of urokinase-Type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 11: 448.
42. Steinberg W (1990) The clinical utility of the CA 19-9 tumor-Associated antigen. Am J Gastroenterol 85: 350-355.
43. Sun C, Rosendahl A, Ansari D, Andersson R (2011) Proteome-based biomarkers in pancreatic cancer. World J Gastroenterol 17: 4845-4852.
44. Sun X, Dong W, Yu B, Luo H, Yu J (2003) Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol 9: 2592-2595.
45. Tempero M, Uchida E, Takasaki H, Burnett D, Steplewski Z, Pour P (1987) Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47: 5501-5503.
46. Ter-Minassian M, Chan J, Hooshmand S, Brais L, Daskalova A, Heafield R, Buchanan L, Qian Z, Fuchs C, Lin X, Christiani D, Kulke M (2013) Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: Results from a prospective institutional database. Endocr Relat Cancer 20: 187-196.
47. Winter J, Yeo C, Brody J (2012) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107: 15-22.
48. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
49. Yang X, Staren E, Howard J, Iwamura T, Bartsch J, Appert H (2001) Invasiveness and MMP expression in pancreatic carcinoma. J Surg Res 98: 33-39.
50. Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J, Abdalla E, Fleming J, Vauthey J, Rashid A, Evans D (2008) One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072.
51. Yao J, Pavel M, Phan A, Kulke M, Hoosen St S, Peter J, Cherfi A, Oberg K (2011) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96: 3741-3749.
52. Yeo T, Hruban R, Leach S, Wilentz R, Sohn T, Kern S, Iacobuzio-Donahue C, Maitra A, Goggins M, Canto M, Abrams R, Laheru D, Jaffee E, Hidalgo M, Yeo CJ (2002) Pancreatic cancer. Curr Probl Cancer 26: 176-275.
53. YokoyamaM, Ochi K, IchimuraM, Mizushima T, Shinji T, Koide N, Tsurumi T, Hasuoka H, Harada M (2002) Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 24: 344-347.
54. Zatelli M, Torta M, Leon A, Ambrosio M, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, degli Uberti E (2007) Chromogranin A as a marker of neuroendocrine neoplasia: An Italian Multicenter Study. Endocr Relat Cancer 14: 473-482.
55. Zhou W, Sokoll L, Bruzek D, Zhang L, Velculescu V, Goldin S, Hruban R, Kern S, Hamilton S, Chan D, Vogelstein B, Kinzler K (1998) Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 7: 109-112.
56. Zhou X, Obuchowski N, McClish D (2011) Statistical Methods in Diagnostic Medicine, 2nd edn, 13-55. John Wiley: New York.